FDA CBER regulatory intelligence for biotech analysts.
Biotech analysts at small healthcare-focused funds need every FDA approval, every CRL, every advisory committee outcome — within minutes of publication, not days. A two-person investment team cannot afford a Clarivate Cortellis subscription at $15,000 per year per seat. Cresthaven Analytics delivers FDA CDER, CBER, CDRH, EMA, MHRA, and 75 other agencies as structured briefs from $149 per month.
What FDA CBER does
The FDA Center for Biologics Evaluation and Research regulates biological products including vaccines, blood products, cell and gene therapies, allergenic products, and human tissue. CBER publishes BLA approvals (including breakthrough designations and priority review vouchers), advisory committee outcomes, RMAT designations, post-market safety actions, and guidance for the rapidly evolving cell and gene therapy space. For biotech analysts and any investor tracking gene therapy, mRNA platforms, or oncology biologics, CBER is the highest-velocity FDA center for material approvals.
Why biotech analysts need FDA CBER intelligence
For biotech analysts tracking gene therapy, cell therapy, mRNA platforms, and vaccine pipelines, FDA CBER is the highest-velocity regulator. The center has accelerated rapidly on novel modalities — RMAT designations, Commissioner National Priority Vouchers, expedited BLA pathways — and individual CBER approvals frequently establish precedent for entire therapy classes. A first-in-class gene therapy approval can reset analyst models across a dozen comparable pipeline programs within the same trading day.
Recent FDA CBER brief from Cresthaven
April 23, 2026 · 14:15 UTC
FDA approves Otarmeni, the first-ever gene therapy for genetic hearing loss, under the Commissioner's National Priority Voucher pilot in 61 days — tied for the fastest BLA approval in modern FDA history
The FDA's Center for Biologics Evaluation and Research has approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy and the first gene therapy product approved for the treatment of genetic hearing loss. The approval was issued 61 days after BLA filing — tied for the fastest Biologics License Application approval in modern FDA history — under the Commissioner's National Priority Voucher (CNPV) pilot program, marking the sixth approval under the program and the first gene therapy to clear the expedited pathway. The action signals a structural acceleration of CBER's gene therapy review timelines and the operational maturation of the National Priority Voucher pathway.
Read the full brief →Recommended tier for biotech analysts
Executive ($999/month)
Up to 30 agencies covers the full healthcare regulatory universe (all three FDA centers, EMA, MHRA, EU SANTE, PMDA, TGA, HSA, plus CMS for reimbursement) with priority alerts for material developments. For an analyst at a smaller fund, Professional at $399/month covers 6 agencies — pick the three FDA centers plus EMA, MHRA, CMS.
View all tiers →Frequently asked
Does Cresthaven cover CBER gene therapy approvals including RMAT and Priority Review Voucher actions?
Yes. The FDA Biologics vertical covers BLA approvals (including breakthrough designations, RMAT, Priority Review Vouchers), advisory committee outcomes, post-market safety actions, and guidance for cell and gene therapy. Material first-in-class and platform-establishing approvals receive high-materiality classification with cross-pipeline implication framing.
How does CBER coverage handle the cell and gene therapy regulatory shifts?
CBER has been evolving its regulatory approach to cell and gene therapy rapidly, including the OTAT-to-OTP restructuring and new pathway guidance for autologous and allogeneic products. Cresthaven briefs flag both individual approval events and the underlying regulatory framework changes, with framing on which platforms and modalities are affected.
Does Cresthaven cover CBER vaccine approvals and post-market actions?
Yes. Vaccine BLA approvals, sBLA supplements, EUA actions, VRBPAC advisory committee outcomes, and post-market safety actions are all covered. The materiality triage distinguishes routine seasonal updates from novel vaccine platform approvals with broader implications.
How does Cresthaven CBER coverage pair with EMA for cross-jurisdictional biotech investing?
CBER and EMA are separate verticals — together they cover the two largest biologics regulators globally. A small biotech fund typically subscribes to both (Basic at $149/month with CBER + EMA + a third regulator like MHRA, or Professional at $399/month adding CDER + CDRH + CMS for full healthcare coverage). Cross-jurisdictional pattern detection in Professional surfaces approval-precedent flows from EMA to FDA and vice versa.